An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Graphite Bio, Inc. (NASDAQ: GRPH) announced that CEO Josh Lehrer, M.D., will speak at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. The discussion will focus on gene editing and will be available for live streaming on Graphite Bio's website. The company is engaged in developing targeted gene integration therapies aimed at treating serious diseases. Graphite Bio leverages a unique gene editing platform to correct mutations and replace disease-causing genes.
Positive
CEO Josh Lehrer to participate in a prominent health care conference, enhancing visibility for the company.
Focus on targeted gene integration positions Graphite Bio in a crucial segment within gene therapy.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., chief executive officer of Graphite Bio, will be a featured speaker on the gene editing corporate panel discussion at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022, at 12:50 p.m. ET.
The panel discussion will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
